DK2591363T3 - Diagnose og behandling af brystcancer - Google Patents
Diagnose og behandling af brystcancer Download PDFInfo
- Publication number
- DK2591363T3 DK2591363T3 DK11804337.1T DK11804337T DK2591363T3 DK 2591363 T3 DK2591363 T3 DK 2591363T3 DK 11804337 T DK11804337 T DK 11804337T DK 2591363 T3 DK2591363 T3 DK 2591363T3
- Authority
- DK
- Denmark
- Prior art keywords
- ctc
- expression
- ctcs
- positive
- breast cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Data Mining & Analysis (AREA)
Claims (8)
1. fremgangsmåde til bestemmelse af et behandlingsforløb, omfattende a) at detektere niveauet af cirkulerende tumorceller (CTC) i en prøve fra et individ med metastatisk brystcancer; b) at bestemme antalllet af CTC, der er positive for ekspression af østrogenreceptor, HER-2, bcl-2 og ki67; c) at beregne et numerisk CTC-endokrin terapi-indeks (CTC-ETI) baseret på antallet af CTC, der er positive for ekspression af østrogenreceptoren (ER), HER-2, bcl-2, ki67, og det samlede antal af CTC ved at tildele point på basis af antallet af CTC, der er positive for ekspression of ER, HER-2, bcl-2 og ki67 på CTC'erne, hvor CTC-ETI'et beregnes ved i) at tildele nul point, når antallet af CTC er 0-4 pr. 7,5 ml, 1 point, når antallet af CTC er 5-10 pr. 7,5 ml, og 2 point, når antallet af CTC er større end 10 pr. 7,5 ml; ii) at tildele nul point, når antallet af CTC, der er positive for ekspression af østrogenreceptor, er større end 10 %, at tildele 2 point, når antallet af CTC, der er positive for ekspression af østrogenreceptor, er 1-10 %, og at tildele 6 point, når antallet af CTC, der er positive for ekspression af østrogenreceptor, er nul; iii) at tildele nul point, når antallet af CTC, der er positive for ekspression af HER-2, er 0 %, at tildele 1 point, når antallet af CTC, der er positive for ekspression af HER-2, er 1-10 %, og at tildele 2 point, når antallet af CTC, der er positive for ekspression af HER-2, er større end 10 %; iv) at tildele nul point, når antallet af CTC, der er positive for ekspression af bcl-2, er større end 10 %, at tildele 1 point, når antallet af CTC, der er positive for ekspression af bcl-2, er 1-10 %, og at tildele 2 point, når antallet af CTC, der er positive for ekspression af bcl-2, er 0 %; v) at tildele nul point, når antallet af CTC, der er positive for ekspression af ki67, er 0 %, at tildele 1 point, når antallet af CTC, der er positive for ekspression af ki-67, er 1-10 %, og at tildele 2 point, når antallet af CTC, der er positive for ekspression af ki-67, er større end 10 %; og vi) at addere pointene til opnåelse af CTC-ETI'et; og d) at anbefale indgivelse af antiøstrogen-terapi til individet, når CTC-ETI'et er 0-3, og indgivelse af kemoterapi til individet, når CTC-ETI'et er 7-14, hvor et CTC-ETI på 0-3 indikerer et gunstigt respons på antiøstrogen-terapi, et CTC- ETI på 4-6 indikerer et moderat respons på antiøstrogen-terapi, og et CTC-ETI på 7-14 indikerer et dårligt respons på antiøstrogen-terapi.
2. Fremgangsmåde ifølge krav 1, hvor behandlingsforløbet omfatter antiøstrogen-terapi.
3. Fremgangsmåde ifølge krav 2, hvor antiøstrogen-terapien omfatter tamoxifen.
4. Fremgangsmåde ifølge krav 2, hvor antiøstrogen-terapien er udvalgt fra gruppen bestående af letrozol, anastrozol og exemestan.
5. Fremgangsmåde ifølge krav 1, hvor behandlingsforløbet omfatter kemoterapi.
6. Fremgangsmåde ifølge krav 1, hvor en eller flere af tumormarkørerne de-tekteres under anvendelse af en multiplex-PCR-fremgangsmåde.
7. Fremgangsmåde ifølge krav 1, hvor tumormarkørerne detekteres under anvendelse af et immunomagnetisk assay.
8. Fremgangsmåde ifølge krav 1, hvor brystcanceren er østrogenreceptor-positiv.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36202110P | 2010-07-07 | 2010-07-07 | |
US201161469890P | 2011-03-31 | 2011-03-31 | |
PCT/US2011/043189 WO2012006421A2 (en) | 2010-07-07 | 2011-07-07 | Diagnosis and treatment of breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2591363T3 true DK2591363T3 (da) | 2017-12-11 |
Family
ID=45438858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11804337.1T DK2591363T3 (da) | 2010-07-07 | 2011-07-07 | Diagnose og behandling af brystcancer |
Country Status (11)
Country | Link |
---|---|
US (3) | US8790878B2 (da) |
EP (2) | EP3306321A1 (da) |
JP (1) | JP5951603B2 (da) |
CN (1) | CN103109187B (da) |
AU (1) | AU2011274789B2 (da) |
BR (1) | BR112013000433A2 (da) |
CA (1) | CA2804269A1 (da) |
DK (1) | DK2591363T3 (da) |
ES (1) | ES2652600T3 (da) |
RU (1) | RU2550925C2 (da) |
WO (1) | WO2012006421A2 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011274789B2 (en) | 2010-07-07 | 2014-04-10 | The Regents Of The University Of Michigan | Diagnosis and treatment of breast cancer |
WO2012097820A1 (en) * | 2011-01-20 | 2012-07-26 | Syddansk Universitet | Method and assay for predicting long-term efficacy of tamoxifen treatment in estrogen receptor-positive breast cancer patients |
US20120252038A1 (en) * | 2011-04-01 | 2012-10-04 | Chianese David A | Steroid receptor assays |
RU2646498C2 (ru) * | 2012-01-24 | 2018-03-05 | Пфайзер Инк. | Способы детектирования 5Т4-положительных циркулирующих опухолевых клеток и способы диагностики 5Т4-положительного рака у млекопитающего |
CN105209489B (zh) * | 2013-03-05 | 2019-06-14 | 得克萨斯州大学系统董事会 | 针对间质和上皮-间质转化的循环肿瘤细胞的特异性检测工具 |
ES2729638T3 (es) * | 2013-10-11 | 2019-11-05 | Ventana Med Syst Inc | Ensayos múltiplex de tinción conjunta de receptores de HER2 y de estrógenos para detectar heterogeneidad tumoral |
CA2934618A1 (en) * | 2013-12-20 | 2015-06-25 | Optipharm. Co., Ltd. | Quantitative reverse transcription polymerase chain reaction kit using tissue and blood for early diagnosis and screening test for therapeutic agent of breast cancer |
CA2934344A1 (en) | 2013-12-20 | 2015-06-25 | David T. TING | Methods and assays relating to circulating tumor cells |
JP6582486B2 (ja) * | 2015-03-27 | 2019-10-02 | コニカミノルタ株式会社 | 血液中の稀少細胞検出方法 |
CN104892759B (zh) * | 2015-06-18 | 2018-04-03 | 福州迈新生物技术开发有限公司 | 由杂交瘤细胞系分泌的抗Ki67单克隆抗体及其应用 |
CN104991010B (zh) * | 2015-07-29 | 2017-10-13 | 中国药科大学 | 一种区分乳腺癌亚型生物标志物的组合物 |
RU2641158C2 (ru) * | 2016-02-03 | 2018-01-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Нижегородская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НижГМА Минздрава России) | Способ оценки эффективности неоадъювантной полихимиотерапии злокачественной опухоли молочной железы |
RU2624367C1 (ru) * | 2016-05-12 | 2017-07-03 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ выбора объема локорегионарной лучевой терапии после хирургической операции по поводу рака молочной железы |
SG10202100951SA (en) | 2016-11-21 | 2021-03-30 | Nanostring Technologies Inc | Chemical compositions and methods of using same |
RU2637859C1 (ru) * | 2017-02-13 | 2017-12-07 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Способ дифференцированного лечения больных локализованным раком молочной железы |
CA3099909A1 (en) | 2018-05-14 | 2019-11-21 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
RU2706029C1 (ru) * | 2018-10-09 | 2019-11-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ лечения люминального подтипа рака молочной железы |
CN111661161B (zh) | 2020-06-08 | 2021-06-08 | 浙江联控技术有限公司 | 一种用于车辆的拖车装置及车辆 |
RU2760168C1 (ru) * | 2021-02-05 | 2021-11-22 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Способ прогнозирования результатов лечения эмбриональных опухолей |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
EP0232967B1 (en) | 1986-01-10 | 1993-04-28 | Amoco Corporation | Competitive homogeneous assay |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5283174A (en) | 1987-09-21 | 1994-02-01 | Gen-Probe, Incorporated | Homogenous protection assay |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5225326A (en) | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
US5480784A (en) | 1989-07-11 | 1996-01-02 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
US5545524A (en) | 1991-12-04 | 1996-08-13 | The Regents Of The University Of Michigan | Compositions and methods for chromosome region-specific probes |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
JP3189000B2 (ja) | 1994-12-01 | 2001-07-16 | 東ソー株式会社 | 特定核酸配列の検出方法 |
US5710029A (en) | 1995-06-07 | 1998-01-20 | Gen-Probe Incorporated | Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
US6121489A (en) | 1996-03-05 | 2000-09-19 | Trega Biosciences, Inc. | Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein |
DE69738687D1 (de) | 1996-04-12 | 2008-06-26 | Phri Properties Inc | Sonden, kits und assays |
US20020172987A1 (en) * | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
AU762728B2 (en) | 1998-07-02 | 2003-07-03 | Gen-Probe Incorporated | Molecular torches |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
US6303305B1 (en) | 1999-03-30 | 2001-10-16 | Roche Diagnostics, Gmbh | Method for quantification of an analyte |
DE60014762T2 (de) | 1999-05-24 | 2005-10-13 | Tosoh Corp., Shinnanyo | Methode zum Nachweis von Ribonukleinsäuren |
KR20030080002A (ko) * | 2001-02-16 | 2003-10-10 | 이뮤니베스트 코포레이션 | 순환 암 세포를 신속하고 효과적으로 분리하기 위한 방법및 시약 |
US7863012B2 (en) * | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
US20050079557A1 (en) * | 2002-03-13 | 2005-04-14 | Bio Merieux | Method for the detection and/or characterisation of circulating tumour cells and the use thereof in the early diagnosis, prognosis and diagnosis of relapses and in the selection and evaluation of therapeutic treatments |
EP1400806A1 (en) * | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
JP4593557B2 (ja) * | 2003-02-27 | 2010-12-08 | ベリデックス・リミテッド・ライアビリティ・カンパニー | 循環腫瘍細胞(ctc):転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価 |
AU2004235747B2 (en) | 2003-05-01 | 2009-05-28 | Gen-Probe Incorporated | Oligonucleotides comprising a molecular switch |
AU2005280162B2 (en) | 2004-08-27 | 2012-04-26 | Gen-Probe Incorporated | Single-primer nucleic acid amplification methods |
EP1797431B1 (en) * | 2004-10-06 | 2011-01-26 | Wellstat Biologics Corporation | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment |
WO2006121991A2 (en) * | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
US20080275652A1 (en) * | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
US20070037173A1 (en) * | 2005-08-12 | 2007-02-15 | Allard Jeffrey W | Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients |
CN104673903B (zh) * | 2005-06-20 | 2018-11-13 | 领先细胞医疗诊断有限公司 | 检测单个细胞中的核酸和鉴定异质大细胞群中罕见细胞的方法 |
KR20080066663A (ko) * | 2005-09-21 | 2008-07-16 | 씨씨씨 디아그노스틱스 엘엘씨 | 맞춤화된 항암 화학요법(pac)을 위한 종합적인 진단테스트 방법 |
US20090317836A1 (en) * | 2006-01-30 | 2009-12-24 | The Scripps Research Institute | Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject |
US20070231822A1 (en) * | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
MX2008013331A (es) * | 2006-04-18 | 2008-11-10 | Wellstat Biologics Corp | Deteccion de receptores de esteroides en celulas de carcinoma circulantes y tratamiento. |
US20080113350A1 (en) | 2006-11-09 | 2008-05-15 | Terstappen Leon W M M | Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH) |
EP2155905A1 (en) * | 2007-05-31 | 2010-02-24 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
US20090061456A1 (en) * | 2007-08-30 | 2009-03-05 | Allard William J | Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells |
CN102016581B (zh) * | 2008-02-25 | 2014-07-30 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
US20130178383A1 (en) * | 2008-11-12 | 2013-07-11 | David Spetzler | Vesicle isolation methods |
US20100311601A1 (en) * | 2009-05-01 | 2010-12-09 | Nuvera Biosciences, Inc. | Index of genomic expression of estrogen receptor (er) and er-related genes |
JP5808349B2 (ja) * | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
AU2011274789B2 (en) | 2010-07-07 | 2014-04-10 | The Regents Of The University Of Michigan | Diagnosis and treatment of breast cancer |
-
2011
- 2011-07-07 AU AU2011274789A patent/AU2011274789B2/en not_active Ceased
- 2011-07-07 CA CA2804269A patent/CA2804269A1/en not_active Abandoned
- 2011-07-07 EP EP17184193.5A patent/EP3306321A1/en not_active Withdrawn
- 2011-07-07 DK DK11804337.1T patent/DK2591363T3/da active
- 2011-07-07 ES ES11804337.1T patent/ES2652600T3/es active Active
- 2011-07-07 BR BR112013000433A patent/BR112013000433A2/pt not_active Application Discontinuation
- 2011-07-07 JP JP2013518829A patent/JP5951603B2/ja not_active Expired - Fee Related
- 2011-07-07 US US13/178,128 patent/US8790878B2/en active Active
- 2011-07-07 CN CN201180042787.2A patent/CN103109187B/zh not_active Expired - Fee Related
- 2011-07-07 WO PCT/US2011/043189 patent/WO2012006421A2/en active Application Filing
- 2011-07-07 EP EP11804337.1A patent/EP2591363B1/en not_active Not-in-force
- 2011-07-07 RU RU2013101996/15A patent/RU2550925C2/ru active
-
2014
- 2014-06-13 US US14/304,364 patent/US9568476B2/en active Active
-
2017
- 2017-01-27 US US15/417,880 patent/US10677801B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20140295444A1 (en) | 2014-10-02 |
AU2011274789B2 (en) | 2014-04-10 |
CA2804269A1 (en) | 2012-01-12 |
ES2652600T3 (es) | 2018-02-05 |
WO2012006421A3 (en) | 2012-04-26 |
JP5951603B2 (ja) | 2016-07-13 |
EP2591363B1 (en) | 2017-09-20 |
RU2013101996A (ru) | 2014-08-20 |
JP2013533486A (ja) | 2013-08-22 |
US9568476B2 (en) | 2017-02-14 |
BR112013000433A2 (pt) | 2016-05-17 |
EP3306321A1 (en) | 2018-04-11 |
US20120009582A1 (en) | 2012-01-12 |
US8790878B2 (en) | 2014-07-29 |
RU2550925C2 (ru) | 2015-05-20 |
US20170242011A1 (en) | 2017-08-24 |
CN103109187B (zh) | 2015-03-25 |
WO2012006421A2 (en) | 2012-01-12 |
CN103109187A (zh) | 2013-05-15 |
US10677801B2 (en) | 2020-06-09 |
EP2591363A4 (en) | 2014-01-22 |
EP2591363A2 (en) | 2013-05-15 |
AU2011274789A1 (en) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10677801B2 (en) | Diagnosis and treatment of breast cancer | |
US9822417B2 (en) | Methods and biomarkers for analysis of colorectal cancer | |
US20140057794A1 (en) | Lung cancer signature | |
WO2012068383A2 (en) | ncRNA AND USES THEREOF | |
WO2008130568A1 (en) | Compositions and methods for treating and diagnosing cancer | |
US9506117B2 (en) | Methods and biomarkers for detection and prognosis of cervical cancer | |
WO2018127786A1 (en) | Compositions and methods for determining a treatment course of action | |
CA2669318A1 (en) | Diagnosis and treatment of breast cancer | |
US20150111758A1 (en) | Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer | |
KR20120004286A (ko) | 림프종 진단 또는 예후 마커로서 Pellino 1 | |
WO2023021330A1 (en) | Compositions and methods for determining a treatment course of action | |
JPWO2015105191A1 (ja) | リンパ節腫脹病変の評価方法 | |
WO2022098619A1 (en) | Compositions and methods for improving cancer therapy | |
JP2014533100A (ja) | 結腸直腸癌の分析のための方法およびバイオマーカー | |
JPWO2015115545A1 (ja) | 乳がんの転移又は再発リスクの評価方法 |